Carasent (Q3 Review): Infosolutions and Medsum taking the lead - Redeye

Redeye leaves its Fundamental Value (Base Case) unchanged at SEK34 as higher 2026–27 EBITDA-CAPEX estimates on the Q3 beat are offset by a higher risk-free rate. Medsum and Infosolutions impress, while Germany lags. We still see Carasent as one of our most attractive SaaS cases.

Länk till analysen i sin helhet: https://www.redeye.se/research/1187135/carasent-q3-review?utm_source=finwire&utm_medium=RSS